{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T03:39:55Z","timestamp":1790739595817,"version":"4.1.0"},"reference-count":25,"publisher":"American Society of Hematology","issue":"8","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2008,10,15]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>The International Prognostic Index and the Follicular Lymphoma International Prognostic Index are widely used for the risk assessment of follicular lymphoma (FL). Although molecular studies have provided insight into the biology of FL, no molecular marker has impacted on treatment stratification. Because TP53 mutations are associated with poor prognosis in hematologic malignancies, we investigated the prognostic value of TP53 mutation at diagnosis in FL. Heterozygous TP53 mutation was detected in 12 of 185 (6%) analyzed cases. Mutation was associated with older age (P = .02) and higher International Prognostic Index score (P = .04). On multivariate analysis, TP53 mutation correlated with shorter progression-free survival (P &lt; .001) and overall survival (P = .009). TP53 mutation was associated with low expression of the immune-response 1 gene expression signature (P = .016) and with an unfavorable gene expression-based survival predictor score (P &lt; .001), demonstrating for the first time that molecular features of the malignant cell may correlate with the nature of the immune response in FL.<\/jats:p>","DOI":"10.1182\/blood-2008-05-154013","type":"journal-article","created":{"date-parts":[[2008,7,16]],"date-time":"2008-07-16T00:18:16Z","timestamp":1216167496000},"page":"3126-3129","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":112,"title":["The presence of TP53 mutation at diagnosis of follicular lymphoma identifies a high-risk group of patients with shortened time to disease progression and poorer overall survival"],"prefix":"10.1182","volume":"112","author":[{"given":"Derville","family":"O'Shea","sequence":"first","affiliation":[{"name":"Centre for Medical Oncology, Barts and the London School of Medicine, London, United Kingdom;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ciar\u00e1n","family":"O'Riain","sequence":"additional","affiliation":[{"name":"Centre for Medical Oncology, Barts and the London School of Medicine, London, United Kingdom;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claire","family":"Taylor","sequence":"additional","affiliation":[{"name":"Mutation Detection Facility, St James's University Hospital, Leeds, United Kingdom;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rachel","family":"Waters","sequence":"additional","affiliation":[{"name":"Centre for Statistics in Medicine, Oxford University, Oxford, United Kingdom;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emanuela","family":"Carlotti","sequence":"additional","affiliation":[{"name":"Centre for Medical Oncology, Barts and the London School of Medicine, London, United Kingdom;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Finlay","family":"MacDougall","sequence":"additional","affiliation":[{"name":"Centre for Medical Oncology, Barts and the London School of Medicine, London, United Kingdom;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Gribben","sequence":"additional","affiliation":[{"name":"Centre for Medical Oncology, Barts and the London School of Medicine, London, United Kingdom;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas","family":"Rosenwald","sequence":"additional","affiliation":[{"name":"Institute of Pathology, University of W\u00fcrzburg, W\u00fcrzburg, Germany;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"German","family":"Ott","sequence":"additional","affiliation":[{"name":"Institute of Pathology, University of W\u00fcrzburg, W\u00fcrzburg, Germany;"},{"name":"Department of Clinical Pathology, Robert-Bosch-Krankenhaus, Stuttgart, Germany;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa M.","family":"Rimsza","sequence":"additional","affiliation":[{"name":"Department of Pathology and Arizona Cancer Center, University of Arizona, Tucson;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erlend B.","family":"Smeland","sequence":"additional","affiliation":[{"name":"Department of Immunology, Institute for Cancer Research, Rikshospitalet University Hospital, Oslo, Norway;"},{"name":"Centre for Cancer Biomedicine, Faculty Division, Norwegian Radium Hospital, University of Oslo, Oslo, Norway;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nathalie","family":"Johnson","sequence":"additional","affiliation":[{"name":"Department of Pathology and Division of Medical Oncology, British Columbia Cancer Agency, Vancouver, BC;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elias","family":"Campo","sequence":"additional","affiliation":[{"name":"Hematopathology Section, Department of Pathology, Institut d'Investigacions Biom\u00e8diques August Pi i Sunyer, University of Barcelona, Barcelona, Spain;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Timothy C.","family":"Greiner","sequence":"additional","affiliation":[{"name":"Department of Pathology and Microbiology, University of Nebraska Medical Center, Omaha; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wing C.","family":"Chan","sequence":"additional","affiliation":[{"name":"Department of Pathology and Microbiology, University of Nebraska Medical Center, Omaha; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Randy D.","family":"Gascoyne","sequence":"additional","affiliation":[{"name":"Department of Pathology and Division of Medical Oncology, British Columbia Cancer Agency, Vancouver, BC;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"George","family":"Wright","sequence":"additional","affiliation":[{"name":"Biometric Research Branch and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Louis M.","family":"Staudt","sequence":"additional","affiliation":[{"name":"Metabolism Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health (NIH), Bethesda, MD"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T. Andrew","family":"Lister","sequence":"additional","affiliation":[{"name":"Centre for Medical Oncology, Barts and the London School of Medicine, London, United Kingdom;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jude","family":"Fitzgibbon","sequence":"additional","affiliation":[{"name":"Centre for Medical Oncology, Barts and the London School of Medicine, London, United Kingdom;"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"key":"2019111611323616400_B1","doi-asserted-by":"crossref","first-page":"1470","DOI":"10.1200\/JCO.1986.4.10.1470","article-title":"Follicular lymphoma: prognostic factors for response and survival.","volume":"4","author":"Gallagher","year":"1986","journal-title":"J Clin Oncol"},{"key":"2019111611323616400_B2","first-page":"75","article-title":"Natural history of and therapy for the indolent non-Hodgkin's lymphomas.","volume":"20","author":"Horning","year":"1993","journal-title":"Semin Oncol"},{"key":"2019111611323616400_B3","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1200\/JCO.1983.1.1.11","article-title":"Histologic conversion in the non-Hodgkin's lymphomas.","volume":"1","author":"Acker","year":"1983","journal-title":"J Clin Oncol"},{"key":"2019111611323616400_B4","doi-asserted-by":"crossref","first-page":"1587","DOI":"10.1200\/JCO.1997.15.4.1587","article-title":"Incidence, predictive factors, and outcome of lymphoma transformation in follicular lymphoma patients.","volume":"15","author":"Bastion","year":"1997","journal-title":"J Clin Oncol"},{"key":"2019111611323616400_B5","doi-asserted-by":"crossref","first-page":"1582","DOI":"10.1200\/JCO.2005.03.3696","article-title":"Improvement of overall and failure-free survival in stage IV follicular lymphoma: 25 years of treatment experience at the University of Texas M.D. Anderson Cancer Center.","volume":"24","author":"Liu","year":"2006","journal-title":"J Clin Oncol"},{"key":"2019111611323616400_B6","doi-asserted-by":"crossref","first-page":"8447","DOI":"10.1200\/JCO.2005.03.1674","article-title":"New treatment options have changed the survival of patients with follicular lymphoma.","volume":"23","author":"Fisher","year":"2005","journal-title":"J Clin Oncol"},{"key":"2019111611323616400_B7","doi-asserted-by":"crossref","first-page":"2077","DOI":"10.1002\/cncr.22649","article-title":"Introduction of rituximab in front-line and salvage therapies has improved outcome of advanced-stage follicular lymphoma patients.","volume":"109","author":"Sacchi","year":"2007","journal-title":"Cancer"},{"key":"2019111611323616400_B8","doi-asserted-by":"crossref","first-page":"1258","DOI":"10.1182\/blood-2003-12-4434","article-title":"Follicular lymphoma international prognostic index.","volume":"104","author":"Solal-Celigny","year":"2004","journal-title":"Blood"},{"key":"2019111611323616400_B9","doi-asserted-by":"crossref","first-page":"1504","DOI":"10.1182\/blood-2006-01-013367","article-title":"The Follicular Lymphoma International Prognostic Index (FLIPI) separates high-risk from intermediate- or low-risk patients with advanced-stage follicular lymphoma treated front-line with rituximab and the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) with respect to treatment outcome.","volume":"108","author":"Buske","year":"2006","journal-title":"Blood"},{"key":"2019111611323616400_B10","doi-asserted-by":"crossref","first-page":"2159","DOI":"10.1056\/NEJMoa041869","article-title":"Prediction of survival in follicular lymphoma based on molecular features of tumor-infiltrating immune cells.","volume":"351","author":"Dave","year":"2004","journal-title":"N Engl J Med"},{"key":"2019111611323616400_B11","doi-asserted-by":"crossref","first-page":"4764","DOI":"10.1182\/blood-2007-10-115915","article-title":"Clinical quantitation of immune signature in follicular lymphoma by RT-PCR-based gene expression profiling.","volume":"111","author":"Byers","year":"2008","journal-title":"Blood"},{"key":"2019111611323616400_B12","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1002\/humu.10081","article-title":"The IARC TP53 database: new online mutation analysis and recommendations to users.","volume":"19","author":"Olivier","year":"2002","journal-title":"Hum Mutat"},{"key":"2019111611323616400_B13","doi-asserted-by":"crossref","first-page":"2391","DOI":"10.1182\/blood.V84.8.2391.2391","article-title":"Structure and function of p53 in normal cells and their aberrations in cancer cells: projection on the hematologic cell lineages.","volume":"84","author":"Prokocimer","year":"1994","journal-title":"Blood"},{"key":"2019111611323616400_B14","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1046\/j.1365-2141.1997.2403057.x","article-title":"The clinical significance of mutations of the P53 tumour suppressor gene in haematological malignancies.","volume":"98","author":"Preudhomme","year":"1997","journal-title":"Br J Haematol"},{"key":"2019111611323616400_B15","doi-asserted-by":"crossref","first-page":"3475","DOI":"10.1038\/sj.onc.1205322","article-title":"Tumor suppressor genes in normal and malignant hematopoiesis.","volume":"21","author":"Krug","year":"2002","journal-title":"Oncogene"},{"key":"2019111611323616400_B16","doi-asserted-by":"crossref","first-page":"4078","DOI":"10.1182\/blood.V90.10.4078","article-title":"Correlation between mutation in P53, p53 expression, cytogenetics, histologic type, and survival in patients with B-cell non-Hodgkin's lymphoma.","volume":"90","author":"Koduru","year":"1997","journal-title":"Blood"},{"key":"2019111611323616400_B17","doi-asserted-by":"crossref","first-page":"1994","DOI":"10.1182\/blood.V82.7.1994.1994","article-title":"p53 mutation is associated with progression in follicular lymphomas.","volume":"82","author":"Sander","year":"1993","journal-title":"Blood"},{"key":"2019111611323616400_B18","doi-asserted-by":"crossref","first-page":"2289","DOI":"10.1182\/blood.V82.8.2289.2289","article-title":"p53 mutations are associated with histologic transformation of follicular lymphoma.","volume":"82","author":"Lo Coco","year":"1993","journal-title":"Blood"},{"key":"2019111611323616400_B19","first-page":"673","article-title":"Transformation of follicular lymphoma: expression of p53 and bcl-2 oncoprotein, apoptosis and cell proliferation.","volume":"39","author":"Symmans","year":"1995","journal-title":"Acta Cytol"},{"key":"2019111611323616400_B20","doi-asserted-by":"crossref","first-page":"1459","DOI":"10.1038\/sj.leu.2403802","article-title":"A limited role for TP53 mutation in the transformation of follicular lymphoma to diffuse large B-cell lymphoma.","volume":"19","author":"Davies","year":"2005","journal-title":"Leukemia"},{"key":"2019111611323616400_B21","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1038\/35106009","article-title":"Assessing TP53 status in human tumours to evaluate clinical outcome.","volume":"1","author":"Soussi","year":"2001","journal-title":"Nat Rev Cancer"},{"key":"2019111611323616400_B22","first-page":"365","article-title":"Primer3 on the WWW for general users and for biologist programmers.","volume":"132","author":"Rozen","year":"2000","journal-title":"Methods Mol Biol"},{"key":"2019111611323616400_B23","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1002\/humu.20495","article-title":"Impact of mutant p53 functional properties on TP53 mutation patterns and tumor phenotype: lessons from recent developments in the IARC TP53 database.","volume":"28","author":"Petitjean","year":"2007","journal-title":"Hum Mutat"},{"key":"2019111611323616400_B24","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1200\/JCO.2005.03.1021","article-title":"Select high-risk genetic features predict earlier progression following chemoimmunotherapy with fludarabine and rituximab in chronic lymphocytic leukemia: justification for risk-adapted therapy.","volume":"24","author":"Byrd","year":"2006","journal-title":"J Clin Oncol"},{"key":"2019111611323616400_B25","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1182\/blood-2007-01-067579","article-title":"In vivo p53 response and immune reaction underlie highly effective low-dose radiotherapy in follicular lymphoma.","volume":"110","author":"Knoops","year":"2007","journal-title":"Blood"}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/112\/8\/3126\/1307699\/zh802008003126.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/112\/8\/3126\/1307699\/zh802008003126.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,11,16]],"date-time":"2019-11-16T11:32:50Z","timestamp":1573903970000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/112\/8\/3126\/114939\/The-presence-of-TP53-mutation-at-diagnosis-of"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,10,15]]},"references-count":25,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2008,10,15]]}},"URL":"https:\/\/doi.org\/10.1182\/blood-2008-05-154013","relation":{},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published":{"date-parts":[[2008,10,15]]}}}